Production (Stage)
BetterLife Pharma Inc.
BETR
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.04% | 60.40% | 79.64% | -33.84% | -34.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.47% | 44.87% | 51.21% | -30.58% | -33.92% |
| Operating Income | 39.47% | -44.87% | -51.21% | 30.58% | 33.92% |
| Income Before Tax | 56.89% | -22.48% | -26.17% | 40.33% | 46.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.89% | -22.48% | -26.17% | 40.33% | 46.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 98.68% | 1,219.64% | -195.07% | -150.10% | -150.45% |
| Net Income | 61.39% | -19.36% | -82.50% | 23.81% | 31.47% |
| EBIT | 39.47% | -44.87% | -51.21% | 30.58% | 33.92% |
| EBITDA | -- | -- | 76.95% | 79.37% | 65.69% |
| EPS Basic | 64.26% | -11.86% | -61.11% | 41.11% | 47.57% |
| Normalized Basic EPS | 57.26% | -25.87% | -155.43% | 17.01% | 27.33% |
| EPS Diluted | 57.38% | -1.22% | -28.04% | 45.06% | 49.50% |
| Normalized Diluted EPS | 57.26% | -25.87% | -155.43% | 17.01% | 27.33% |
| Average Basic Shares Outstanding | 12.52% | 13.36% | 16.79% | 20.63% | 25.47% |
| Average Diluted Shares Outstanding | 16.34% | 17.32% | 20.99% | 20.63% | 25.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |